Study guide

3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

Key Takeaways Explain This Topic AI

Endometrial cancer is the most common gynecologic cancer in the United States; about 90% of cases present with postmenopausal or abnormal bleeding, and endometrial sampling is the key first test.

Obesity, unopposed estrogen, chronic anovulation (PCOS), tamoxifen, diabetes, and Lynch syndrome raise endometrial cancer risk; combined hormonal contraception and the LNG-IUS lower it.

Ovarian cancer is the deadliest gynecologic cancer, often presenting with vague bloating, early satiety, and pelvic pain; the USPSTF recommends against screening average-risk women with CA-125 or ultrasound.

Germ cell ovarian tumors affect young women and produce tumor markers: LDH in dysgerminoma, AFP in yolk sac tumor, and hCG in choriocarcinoma.

Any persistent vulvar lesion, especially within lichen sclerosus, needs biopsy because HPV-independent vulvar squamous cell carcinoma arises from differentiated VIN.

Last updated: October 2026

Overview for the WHNP

WHNPs rarely treat gynecologic cancers, but the exam tests whether you recognize warning signs, choose the correct first diagnostic step, and refer appropriately to gynecologic oncology. Early detection is the WHNP's main contribution to survival.

Cancer Key Risk Factors Classic Presentation First Step

Endometrial Obesity, unopposed estrogen, PCOS, tamoxifen, diabetes, nulliparity, Lynch syndrome Postmenopausal bleeding; abnormal bleeding at 45 or older TVUS stripe or endometrial biopsy

Ovarian Age, BRCA1/2, Lynch, endometriosis, nulliparity Bloating, early satiety, pelvic pain, urinary urgency, adnexal mass TVUS and CA-125 (postmenopausal); gynecologic oncology referral

Cervical Persistent high-risk HPV, smoking, HIV, no screening Postcoital bleeding, discharge, visible lesion Biopsy of any visible lesion

  • Vulvar Older age, lichen sclerosus, HPV, smoking Pruritus, plaque, ulcer, or mass Punch biopsy
  • Vaginal HPV, prior cervical neoplasia, in utero DES exposure Bleeding, discharge, mass Biopsy
  • Endometrial Cancer

Endometrial cancer is the most common gynecologic cancer in the United States, and both incidence and mortality have been rising, with a disproportionate mortality burden among Black women.

Endometrioid (traditionally "type I") tumors are estrogen-driven, often preceded by endometrial intraepithelial neoplasia (atypical hyperplasia), and usually low grade.

Non-endometrioid ("type II") tumors (serous, clear cell, carcinosarcoma) are not estrogen-related, occur in older women, and behave aggressively. FIGO's 2023 staging adds molecular classes (POLE-mutated, mismatch repair–deficient, p53-abnormal, and no specific molecular profile).

Presentation: About 90% present with postmenopausal bleeding or abnormal bleeding, so most are found early.

Evaluation: In postmenopausal bleeding, an endometrial thickness of 4 mm or less on TVUS has a high negative predictive value, but persistent bleeding needs sampling regardless. Endometrial biopsy is the standard office test.

Atypical hyperplasia/EIN: Treated with hysterectomy because up to about 40% have concurrent cancer; progestin therapy (often the LNG-IUS) with surveillance is an option when fertility is desired.

Protective factors: Combined hormonal contraceptives (protection persists for years after stopping), the LNG-IUS, pregnancy, and physical activity.

Lynch syndrome: Mismatch-repair gene variants (MLH1, MSH2, MSH6, PMS2) carry a lifetime endometrial cancer risk of up to roughly 40%–60% depending on the gene, plus colorectal and ovarian risk. All endometrial cancers are now tested for mismatch-repair status.

Ovarian Cancer

Ovarian cancer is the most lethal gynecologic cancer because most cases are diagnosed at an advanced stage.

Tumor Types

Category Typical Patient Key Features and Markers

Epithelial (about 90%) Older women High-grade serous is most common and often arises in the fallopian tube ; CA-125 is elevated in most advanced cases

Germ cell Adolescents and young women Dysgerminoma: LDH ; yolk sac tumor: AFP ; choriocarcinoma: hCG ; usually unilateral and highly curable

Sex cord–stromal Any age Granulosa cell: inhibin , estrogen effects (AUB, endometrial hyperplasia, precocious puberty); Sertoli-Leydig: androgens (virilization)

Risk and Protection

Risk: Age, BRCA1 (lifetime ovarian cancer risk about 39%–44%), BRCA2 (about 11%–17%), Lynch syndrome, endometriosis (clear cell and endometrioid types), nulliparity, and infertility.

Protection: Combined oral contraceptives (roughly 50% risk reduction after about 5 or more years), pregnancy, breastfeeding, tubal sterilization, and especially salpingectomy . Risk-reducing salpingo-oophorectomy is advised for BRCA1 carriers at 35–40 and BRCA2 carriers at 40–45 once childbearing is complete.

Symptoms and Screening

Persistent, new symptoms occurring more than 12 times a month, such as bloating, early satiety, pelvic or abdominal pain, and urinary urgency or frequency , warrant evaluation. The USPSTF recommends against screening average-risk women with CA-125 or ultrasound (grade D) because screening did not reduce mortality and led to harmful surgery.

When to Refer an Adnexal Mass to Gynecologic Oncology (ACOG)

Postmenopausal: Elevated CA-125, ascites, a nodular or fixed pelvic mass, or evidence of abdominal or distant metastasis.

Premenopausal: Very elevated CA-125, ascites, or evidence of metastasis.

Either: A high-risk score on a validated tool (O-RADS, IOTA rules, OVA1, or ROMA) or a strong family history of breast or ovarian cancer.

Everyone with epithelial ovarian cancer should be offered germline genetic testing .

Cervical Cancer

Cervical cancer is driven by persistent high-risk HPV ; HPV types 16 and 18 cause about 70%. Squamous cell carcinoma is most common, followed by adenocarcinoma, which screening detects less well. Most cases occur in women who were never screened or were screened inadequately. Warning signs are postcoital bleeding , intermenstrual bleeding, and watery or bloody discharge. A visible cervical lesion needs biopsy even if recent cytology was normal. Early disease is treated surgically; locally advanced disease is treated with chemoradiation.

Vulvar Cancer

About 90% of vulvar cancers are squamous cell carcinomas, arising by two pathways:

HPV-associated: Younger women and smokers, preceded by vulvar HSIL (usual-type VIN).

HPV-independent: Older women, arising from lichen sclerosus through differentiated VIN (dVIN) .

Presentation is chronic pruritus , a plaque, an ulcer, or a mass. Biopsy any persistent, changing, pigmented, or nonhealing vulvar lesion, especially in lichen sclerosus that does not respond to clobetasol. Melanoma is the second most common vulvar malignancy.

Vaginal Cancer

Primary vaginal cancer is rare ; most vaginal malignancies are metastases from the cervix or endometrium. Primary squamous cell carcinoma is HPV-related and more common after prior cervical neoplasia. Clear cell adenocarcinoma is linked to in utero diethylstilbestrol (DES) exposure, which is why women exposed to DES need careful vaginal as well as cervical examination.